Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

Short interest in Iovance Biotherapeutics (IOVA) was 65.2 million shares at the 30 October 2026 settlement, up 10.6% from the 15 October 2026 settlement, with days to cover at 4.2. The next earnings report for Iovance Biotherapeutics is estimated for 23 February 2027.

65.2M

Short interest

settlement 2026-10-30

4.2

Days to cover

-0.3 days vs prior

33.8%

Short share of volume

2026-11-18

53

Fails to deliver

settlement 2026-10-30

Tue 23 Feb

Next earnings

estimated date

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-18.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 30 October 2026, short interest in IOVA is 65,189,660 shares, up 362,630 shares over the last month. Over the last 48 readings it ranged from 53,988,814 shares (15 November 2024) to 131,334,639 shares (13 February 2026). At the reported average volume of 15.6M shares a day that is 4.2 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/iova" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-3065,189,660+10.6%15,639,9024.17
2026-10-1558,925,298-9.1%13,310,5844.43
2026-09-3064,827,030-25.6%22,908,1602.83
2026-09-1587,127,871-1.1%11,730,2167.43
2026-08-3188,138,991-14.4%16,696,0485.28
2026-08-14102,940,590+3.0%21,509,7524.79
2026-07-3199,975,709+0.1%15,923,7536.28
2026-07-1599,892,938-0.6%16,903,8175.91
2026-06-30100,526,623-2.9%14,159,7367.10
2026-06-15103,489,642-0.7%13,107,5777.90
2026-05-29104,249,751-2.2%12,722,7988.19
2026-05-15106,608,353-7.1%17,782,4386.00
2026-04-30114,711,667+5.4%12,535,6519.15
2026-04-15108,804,045-1.8%16,639,9676.54
2026-03-31110,832,243-3.7%11,697,7039.47
2026-03-13115,070,206-12.1%23,097,5174.98
2026-02-27130,927,595-0.3%18,040,8217.26
2026-02-13131,334,639+24.8%8,986,76914.61
2026-01-30105,255,004-10.1%13,899,6727.57
2026-01-15117,099,153-1.7%11,562,08110.13
2025-12-31119,070,866-1.1%13,446,5248.86
2025-12-15120,342,810+1.2%9,501,92512.67
2025-11-28118,939,462+2.8%10,055,95711.83
2025-11-14115,733,068+21.3%28,665,7564.04
2025-10-3195,415,882+14.1%12,863,5117.42
2025-10-1583,612,571+14.6%11,319,9367.39
2025-09-3072,971,971+11.1%10,139,6007.20
2025-09-1565,704,715-7.9%9,311,2247.06
2025-08-2971,319,978-0.1%12,497,2395.71
2025-08-1571,364,792+5.4%16,989,2164.20
2025-07-3167,706,980-31.4%31,867,9282.12
2025-07-1598,633,209+1.9%13,682,3867.21
2025-06-3096,777,448+6.4%10,660,4589.08
2025-06-1390,964,131+5.3%13,019,3066.99
2025-05-3086,361,273+12.1%12,171,9587.10
2025-05-1577,018,516+3.3%25,407,2433.03
2025-04-3074,567,033+4.5%8,321,5138.96
2025-04-1571,372,146-5.1%10,833,3786.59
2025-03-3175,186,511+11.7%8,044,0059.35
2025-03-1467,304,707+12.9%10,982,7066.13
2025-02-2859,585,491-6.3%12,772,6854.67
2025-02-1463,597,563-0.5%7,298,1598.71
2025-01-3163,909,963+3.1%7,900,5848.09
2025-01-1561,984,016+1.1%10,543,5995.88
2024-12-3161,305,700+3.3%7,114,4278.62
2024-12-1359,327,307+4.2%4,518,23613.13
2024-11-2956,916,236+5.4%7,552,3437.54
2024-11-1553,988,814-9.6%10,246,3485.27

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 18 November 2026, the short share of IOVA volume is 33.8%, down 11.2 points over the last five sessions. Over the last 30 readings it ranged from 30.9% (30 October 2026) to 49.1% (4 November 2026). The latest reading is 5.2 points below the 30-session average of 39.0%, on 3.3M shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-181.1M3.3M33.8%10,355
2026-11-171.5M4.3M35.4%17,540
2026-11-161.7M3.9M44.4%3,695
2026-11-131.6M4.6M35.4%77,302
2026-11-122.6M5.5M47.0%8,863
2026-11-111.8M4.0M45.1%8,010
2026-11-101.8M4.0M45.9%4,542
2026-11-092.2M5.7M39.6%2,099
2026-11-061.9M4.9M38.3%273,348
2026-11-054.4M10.1M43.6%256,305
2026-11-044.1M8.3M49.1%31,074
2026-11-032.5M6.7M38.1%11,461
2026-11-023.2M10.4M31.1%130,520
2026-10-304.2M13.5M30.9%372,563
2026-10-297.9M22.5M35.1%1,593,625
2026-10-281.4M3.6M39.5%12,451
2026-10-271.5M4.4M35.1%30,850
2026-10-261.3M3.7M35.4%17,937
2026-10-231.7M4.0M41.5%11,424
2026-10-221.9M4.9M39.1%58,361
2026-10-212.5M6.2M40.1%26,886
2026-10-201.8M4.7M38.6%31,452
2026-10-191.6M4.2M38.8%16,209
2026-10-163.0M6.4M48.0%7,655
2026-10-151.5M4.6M31.9%6,321
2026-10-142.1M5.2M39.7%14,914
2026-10-131.7M4.6M37.8%5,695
2026-10-121.4M3.9M35.8%19,115
2026-10-093.2M8.6M37.1%14,789
2026-10-082.4M6.2M38.2%11,144

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 30 October 2026, the fails-to-deliver balance in IOVA is 53 shares, down 212 shares over the last settlement date. Over the last 30 readings it ranged from 53 shares (30 October 2026) to 575,562 shares (9 October 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-10-3053$9.56$507
2026-10-23265$14.14$4K
2026-10-2271,119$14.62$1.0M
2026-10-1913,879$13.62$189K
2026-10-13316$14.56$5K
2026-10-09575,562$13.31$7.7M
2026-10-05579$14.22$8K
2026-10-02120,829$14.23$1.7M
2026-10-012,292$14.82$34K
2026-09-30521,568$14.45$7.5M
2026-09-29234,099$10.99$2.6M
2026-09-281,535$11.00$17K
2026-09-243,672$10.19$37K
2026-09-213,253$10.25$33K
2026-09-1643,674$9.36$409K
2026-09-041,846$8.70$16K
2026-08-319,696$8.01$78K
2026-08-27528$8.08$4K
2026-08-2534,408$8.06$277K
2026-08-249,917$8.29$82K
2026-08-2128,340$8.99$255K
2026-08-185,100$7.10$36K
2026-08-17499$6.98$3K
2026-08-114,096$6.40$26K
2026-08-0713,186$6.21$82K
2026-08-04154,353$4.32$667K
2026-08-03236,695$4.07$963K
2026-07-2439,206$5.13$201K
2026-07-2327,065$5.17$140K
2026-07-2233,525$5.48$184K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for IOVA in the last 90 days. The most recent filings are listed below. Latest filing: Vogt Frederick G (Interim CEO & General Counsel) on 2026-11-11.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-11-11Vogt Frederick GInterim CEO & General CounselTax withholding191K$8.09$1.5M604K
2026-11-11Vogt Frederick GInterim CEO & General CounselExercise or conversion200K$7.55$1.5M795K
2026-11-10Kirby Daniel GordonChief Commercial OfficerTax withholding4K$8.08$32K161K
2026-11-10Kirby Daniel GordonChief Commercial OfficerExercise or conversion10K$0.00$0165K
2026-11-06Roche Corleen M.Chief Financial OfficerTax withholding5K$8.04$43K36K
2026-11-06Roche Corleen M.Chief Financial OfficerExercise or conversion13K$0.00$041K
2026-09-08Vogt Frederick GInterim CEO & General CounselTax withholding7K$8.70$58K595K
2026-09-08Vogt Frederick GInterim CEO & General CounselExercise or conversion16K$0.00$0602K
2026-09-08Puri Raj K.Chief Regulatory OfficerTax withholding4K$8.70$39K256K
2026-09-08Puri Raj K.Chief Regulatory OfficerExercise or conversion10K$0.00$0261K
2026-09-08BILINSKY IGORChief Operating OfficerTax withholding4K$8.70$35K142K
2026-09-08BILINSKY IGORChief Operating OfficerExercise or conversion8K$0.00$0146K
2026-09-01Vogt Frederick GInterim CEO & General CounselTax withholding18K$8.28$147K586K
2026-09-01Vogt Frederick GInterim CEO & General CounselExercise or conversion42K$0.00$0604K
2026-09-01Puri Raj K.Chief Regulatory OfficerTax withholding3K$8.28$21K251K
2026-09-01Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0254K
2026-09-01BILINSKY IGORChief Operating OfficerTax withholding4K$8.28$37K138K
2026-09-01BILINSKY IGORChief Operating OfficerExercise or conversion9K$0.00$0143K
2026-08-10Kirby Daniel GordonChief Commercial OfficerTax withholding2K$6.40$16K155K
2026-08-10Kirby Daniel GordonChief Commercial OfficerExercise or conversion10K$0.00$0157K
2026-08-06Roche Corleen M.Chief Financial OfficerTax withholding21K$6.21$132K29K
2026-08-06Roche Corleen M.Chief Financial OfficerExercise or conversion50K$0.00$050K
2026-06-05Vogt Frederick GInterim CEO & General CounselTax withholding7K$4.23$28K562K
2026-06-05Vogt Frederick GInterim CEO & General CounselExercise or conversion16K$0.00$0569K
2026-06-05Puri Raj K.Chief Regulatory OfficerTax withholding4K$4.23$16K248K
2026-06-05Puri Raj K.Chief Regulatory OfficerExercise or conversion10K$0.00$0252K
2026-06-05GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding4K$4.23$17K140K
2026-06-05GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion8K$0.00$0144K
2026-06-05BILINSKY IGORChief Operating OfficerTax withholding4K$4.23$17K134K
2026-06-05BILINSKY IGORChief Operating OfficerExercise or conversion8K$0.00$0138K
2026-06-01Vogt Frederick GInterim CEO & General CounselTax withholding18K$3.96$70K554K
2026-06-01Vogt Frederick GInterim CEO & General CounselExercise or conversion42K$0.00$0571K
2026-06-01Puri Raj K.Chief Regulatory OfficerTax withholding3K$3.96$10K242K
2026-06-01Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0245K
2026-06-01GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding4K$3.96$18K136K
2026-06-01GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion9K$0.00$0141K
2026-06-01BILINSKY IGORChief Operating OfficerTax withholding4K$3.96$18K130K
2026-06-01BILINSKY IGORChief Operating OfficerExercise or conversion9K$0.00$0135K
2026-05-11Kirby Daniel GordonChief Commercial OfficerTax withholding2K$3.70$9K147K
2026-05-11Kirby Daniel GordonChief Commercial OfficerExercise or conversion10K$0.00$0149K
2026-03-05Vogt Frederick GInterim CEO & General CounselTax withholding27K$4.58$123K530K
2026-03-05Vogt Frederick GInterim CEO & General CounselExercise or conversion62K$0.00$0556K
2026-03-05Puri Raj K.Chief Regulatory OfficerTax withholding18K$4.58$84K239K
2026-03-05Puri Raj K.Chief Regulatory OfficerExercise or conversion39K$0.00$0258K
2026-03-05GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding17K$4.58$76K132K
2026-03-05GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion31K$0.00$0148K
2026-03-05BILINSKY IGORChief Operating OfficerTax withholding17K$4.58$76K126K
2026-03-05BILINSKY IGORChief Operating OfficerExercise or conversion31K$0.00$0142K
2026-03-02Vogt Frederick GInterim CEO & General CounselTax withholding23K$3.79$86K494K
2026-03-02Vogt Frederick GInterim CEO & General CounselExercise or conversion52K$0.00$0517K
2026-03-02Puri Raj K.Chief Regulatory OfficerTax withholding3K$3.79$11K219K
2026-03-02Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0221K
2026-03-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding7K$3.79$27K117K
2026-03-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion13K$0.00$0124K
2026-03-02BILINSKY IGORChief Operating OfficerTax withholding7K$3.79$26K111K
2026-03-02BILINSKY IGORChief Operating OfficerExercise or conversion12K$0.00$0118K
2026-02-24Kirby Daniel GordonChief Commercial OfficerTax withholding34K$3.78$129K139K
2026-02-24Kirby Daniel GordonChief Commercial OfficerExercise or conversion120K$0.00$0174K
2026-02-10Kirby Daniel GordonChief Commercial OfficerTax withholding16K$2.60$43K54K
2026-02-10Kirby Daniel GordonChief Commercial OfficerExercise or conversion40K$0.00$070K
2025-12-02Vogt Frederick GInterim CEO & General CounselTax withholding4K$2.14$9K465K
2025-12-02Vogt Frederick GInterim CEO & General CounselExercise or conversion10K$0.00$0469K
2025-12-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding2K$2.14$4K112K
2025-12-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion4K$0.00$0114K
2025-12-02BILINSKY IGORChief Operating OfficerTax withholding2K$2.14$4K106K
2025-12-02BILINSKY IGORChief Operating OfficerExercise or conversion4K$0.00$0108K
2025-12-01Vogt Frederick GInterim CEO & General CounselTax withholding18K$2.23$39K459K
2025-12-01Vogt Frederick GInterim CEO & General CounselExercise or conversion42K$0.00$0476K
2025-12-01Puri Raj K.Chief Regulatory OfficerTax withholding2K$2.23$6K216K
2025-12-01Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0218K
2025-12-01GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding4K$2.23$10K110K
2025-12-01GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion9K$0.00$0114K
2025-12-01BILINSKY IGORChief Operating OfficerTax withholding4K$2.23$10K104K
2025-12-01BILINSKY IGORChief Operating OfficerExercise or conversion9K$0.00$0108K
2025-09-02Vogt Frederick GInterim CEO & General CounselTax withholding22K$2.19$48K435K
2025-09-02Vogt Frederick GInterim CEO & General CounselExercise or conversion52K$0.00$0457K
2025-09-02Puri Raj K.Chief Regulatory OfficerTax withholding2K$2.19$5K213K
2025-09-02Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0215K
2025-09-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding6K$2.19$14K105K
2025-09-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion13K$0.00$0112K
2025-09-02BILINSKY IGORChief Operating OfficerTax withholding6K$2.19$14K100K
2025-09-02BILINSKY IGORChief Operating OfficerExercise or conversion12K$0.00$0106K
2025-06-05Kirby Daniel GordonChief Commercial OfficerBuy30K$1.84$55K30K
2025-06-02Bellemin Jean-MarcChief Financial OfficerExercise or conversion9K$0.00$065K
2025-06-02Bellemin Jean-MarcChief Financial OfficerTax withholding4K$1.76$8K61K
2025-06-02BILINSKY IGORChief Operating OfficerExercise or conversion12K$0.00$0100K
2025-06-02BILINSKY IGORChief Operating OfficerTax withholding6K$1.76$11K94K
2025-06-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding6K$1.76$11K99K
2025-06-02GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion13K$0.00$0106K
2025-06-02Vogt Frederick GInterim CEO & General CounselTax withholding22K$1.76$39K405K
2025-06-02Vogt Frederick GInterim CEO & General CounselExercise or conversion52K$0.00$0427K
2025-06-02Puri Raj K.Chief Regulatory OfficerTax withholding2K$1.76$4K210K
2025-06-02Puri Raj K.Chief Regulatory OfficerExercise or conversion5K$0.00$0212K
2025-05-23Puri Raj K.Chief Regulatory OfficerBuy6K$1.74$10K207K
2025-05-14Vogt Frederick GInterim CEO & General CounselBuy25K$1.69$42K375K
2025-03-14Puri Raj K.Chief Regulatory OfficerExercise or conversion8K$0.00$0204K
2025-03-14Puri Raj K.Chief Regulatory OfficerTax withholding3K$3.59$9K201K
2025-03-03GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerTax withholding33K$4.04$135K93K
2025-03-03GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerExercise or conversion62K$0.00$0126K
2025-03-03Puri Raj K.Chief Regulatory OfficerTax withholding20K$4.04$81K195K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

1 holder reports 5% or more of IOVA in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 7.5% of the class (33,366,587 shares), filed 2026-07-28 for an event on 2026-06-30.

FiledFormHolderSharesOf classEvent
2026-11-1013GSTATE STREET CORPORATIONparent holding company21.7M4.8%2026-09-30
2026-07-2813G/Ano. 3BlackRock, Inc.parent holding company33.4M7.5%2026-06-30
2026-03-2713G/Ano. 6The Vanguard Groupinvestment adviser00.0%2026-03-13

13F holders

Tracked managers holding IOVA at their latest 13F. JSON

8 of the 30 tracked managers held IOVA at their latest 13F, $484.8M in total at quarter-end prices. Two Sigma Investments is the largest at $221.8M (0.2% of its portfolio) as of 2026-09-30. Over the prior quarter 4 added shares and 4 cut.

FundQuarterSharesValueOf portfolioChange in shares
Two Sigma Investments2026-09-3015.0M$221.8M0.16%-4.0M
D. E. Shaw & Co.2026-09-309.2M$135.8M0.07%+7.0M
AQR Capital Management2026-09-303.7M$55.5M0.02%-128K
Millennium Management2026-09-301.9M$27.7M0.01%-6.7M
Citadel Advisors2026-09-301.2M$17.4M0.00%-933K
Point72 Asset Management2026-09-301.0M$15.1M0.02%new
Bridgewater Associates2026-09-30522K$7.7M0.03%new
Renaissance Technologies2026-09-30258K$3.8M0.01%new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q3 FY 2026 (quarter ended 2026-09-30) Iovance Biotherapeutics reported revenue of $121.5M, up 80.1% from the same quarter a year earlier, and net loss of $22.3M (-0.05 diluted EPS). In FY 2025 it generated -$302.4M of operating cash flow.

Cash
$57.9M
Equity
$812.7M
Total assets
$991.2M
Shares outstanding
462,655,151

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q3 FY 20262026-09-30$121.5M-$22.3M-18.3%-0.05
Q2 FY 20262026-06-30$99.3M-$47.3M-47.6%-0.11
Q1 FY 20262026-03-31$71.4M-$79.0M-110.7%-0.19
Q4 FY 2025derived2025-12-31$86.8M-$71.9M-82.9%n/a
Q3 FY 20252025-09-30$67.5M-$91.3M-135.3%-0.25
Q2 FY 20252025-06-30$60.0M-$111.7M-186.2%-0.33
Q1 FY 20252025-03-31$49.3M-$116.2M-235.5%-0.36
Q4 FY 2024derived2024-12-31$73.7M-$78.6M-106.6%n/a

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$263.5M-$391.0M-$302.4M$33.8Mn/an/a
FY 20242024-12-31$164.1M-$372.2M-$353.0M$11.1Mn/an/a
FY 20232023-12-31$1.2M-$444.0M-$361.8M$22.3Mn/an/a
FY 20222022-12-31n/a-$395.9M-$292.8M$20.4Mn/an/a
FY 20212021-12-31n/a-$342.3M-$227.9M$37.6Mn/an/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2026-10-27 from the cover page.

What this page is

Iovance Biotherapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Iovance Biotherapeutics (IOVA), SEC CIK 1425205, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-30.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-18.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-30.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-11-10.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-09-30.JSON and CSV
Financials
SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-05.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-11-11.JSON and CSV
Company record
EDGAR filing index for CIK 1425205Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Datasets

Frequently Asked Questions

How much of IOVA is sold short?
65,189,660 shares were held short at the 2026-10-30 settlement, 4.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IOVA's daily short volume?
On 2026-11-18, 1,107,380 of the 3,274,698 IOVA shares reported to FINRA were sold short, 33.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IOVA have fails to deliver?
The SEC's latest file shows 53 IOVA shares failed to deliver at settlement 2026-10-30. Fails are reported per settlement date and published twice a month with a lag.
Are IOVA insiders buying or selling?
No open-market insider trades were reported for IOVA in the last 90 days. The most recent filings are listed below. Latest filing: Vogt Frederick G (Interim CEO & General Counsel) on 2026-11-11.
Who owns 5% or more of IOVA?
1 holder reports 5% or more of IOVA in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 7.5% of the class (33,366,587 shares), filed 2026-07-28 for an event on 2026-06-30.
What did IOVA report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-30) Iovance Biotherapeutics reported revenue of $121.5M, up 80.1% from the same quarter a year earlier, and net loss of $22.3M (-0.05 diluted EPS). In FY 2025 it generated -$302.4M of operating cash flow.
Which tracked 13F managers own IOVA?
8 of the 30 tracked 13F managers held IOVA shares at their latest filing, $484.8M in all. The largest: Two Sigma Investments (15.0M shares, $221.8M), D. E. Shaw & Co. (9.2M shares, $135.8M), Cliff Asness's AQR Capital Management (3.7M shares, $55.5M), Izzy Englander's Millennium Management (1.9M shares, $27.7M), Ken Griffin's Citadel Advisors (1.2M shares, $17.4M), Steve Cohen's Point72 Asset Management (1.0M shares, $15.1M). The table above lists all 8.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.